CLINICAL RESPONSE OF ACCELERATED HYPOFRACTIONATED RADIOTHERAPY IN INOPERABLE NON-SMALL CELL LUNG CANCER PATIENTS

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200110001

Enrollment

Unknown

Registered

2020-01-10

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non&#45

Interventions

Radiotherapy treatment After selecting with the inclusion and exclusion criteria&#44

informed consent was taken prior to the study. The consented patients were prepared for radiotherapy. Any infection such as chest infection&#44

oral candidiasis&#44

or pulmonary TB were controlled first before radiotherapy. All patients were Computed Tomography (CT) simulated and immobilized using the following techniques. Immobilization&#45

Patients were positioned supine with arms immobilized above the head in a comfortable&#44

reproducible position to allow a greater choice of beam angle. CT scanning&#45

was obtained from the cricoid cartilage to the superior aspect of the L2 vertebra to allow the lung DVH to be calculated. Ideally 3â€“5 mm slices were used. The parenchymal extent of the GTV was defin

as are lateral reference points. Conformal planning&#45

Beam angles were chosen to reduce lung dose with anterior oblique&#44

posterior oblique and lateral beams often used. Wedges compensated for the obliquity of the beams in relation to the chest wall&#44

and MLC shielding was used to conform each beam shape to the PTV. The V20 (volume of lung minus PTV receiving more than 20Gy) was kept below 32 per cent to avoid pneumonitis. The length of esophagus i

in order to prevent esophagitis. Then&#44

patients were treated with radiotherap

Experimental Radiation

Accelerated hypofractionated radiotherapy with 45 Gy in 15 fractions over 3 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria 1. Unresectable or medically inoperable non-small cell lung cancer patients 2. Patients who are unfit for chemotherapy due to some comorbidities (E.g., poor cardiac, liver or renal function, etc., or old age) 3. Patients with ECOG performance status 0,1 or 2

Exclusion criteria

Exclusion criteria: Exclusion criteria 1. Patients with distant metastasis 2. Patients previously treated with thoracic radiotherapy or chemotherapy 3. Patients with small cell lung cancer

Design outcomes

Primary

Measure	Time frame
Clinical response 6 weeks after radiotherapy RECIST guideline version 1.1 (CT scan chest)	—

Secondary

Measure	Time frame
Acute toxicities pretreatment (baseline), weekly during radiotherapy, 6 weeks and 12 weeks after radiotherapy CTCAE version 5 (symptons assessment)	—

Countries

Myanmar

Contacts

Public ContactShoon Mya Aye

Department of Radiotherapy, Yangon General Hospital

drshoonmyaaye89@gmail.com+959977235193

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

CLINICAL RESPONSE OF ACCELERATED HYPOFRACTIONATED RADIOTHERAPY IN INOPERABLE NON&#45;SMALL CELL LUNG CANCER PATIENTS